Fig. 4: Treatment with rAAV-HOPE in a colorectal cancer mouse model.
From: NF-κB-activated oncogene inhibition strategy for cancer gene therapy
A Schematic diagram of the establishment of the CT-26 colorectal cancer (CRC) mouse model and treatment schedule. The CRC mouse model was established by subcutaneous (s.c.) injection of CT-26 cells, and the mice were then subjected to intravenous (i.v.) injection of phosphate-buffered saline (PBS) (n = 8), rAAV-HOPE-mPLK1 (n = 8), rAAV-HOPE-mMYC (n = 8), rAAV-HOPE-mKRAS (n = 8), or rAAV-HOPE-mTPMK (n = 8). B Body weight changes in CRC model mice post-tumour cell inoculation. C Tumour size in CRC model mice intravenously injected with PBS or various types of rAAV-HOPE. D Images of tumours from CRC model mice intravenously injected with PBS or various types of rAAV-HOPE. E Tumour size as determined from harvested tumour tissues. F Tumour weights as determined from harvested tumour tissues. G Images of spleens from colon cancer model mice intravenously injected with PBS and various types of rAAV-HOPE. H Weights of harvested spleens. I Measurement of serum biochemical indicators of kidney function. J Measurement of serum biochemical indicators of liver function. mPLK1/mMYC/mKRAS/mTPMK, rAAV-HOPE-mPLK1/rAAV-HOPE-mMYC/rAAV-HOPE-mKRAS/rAAV-HOPE-mTPMK.
